Teva Pharmaceutical Industries (TEVA) Releases FY18 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $2.25-2.50 for the period, compared to the Thomson Reuters consensus estimate of $2.99. The company issued revenue guidance of $18.3-18.8 billion, compared to the consensus revenue estimate of $19.36 billion.

Several brokerages have issued reports on TEVA. Piper Jaffray Companies downgraded Teva Pharmaceutical Industries from a neutral rating to an underweight rating and set a $11.00 price target for the company. in a report on Friday. Gabelli downgraded Teva Pharmaceutical Industries from a buy rating to a hold rating and set a $19.00 price target for the company. in a report on Friday. Deutsche Bank set a $18.00 price objective on Teva Pharmaceutical Industries and gave the stock a hold rating in a research report on Friday. Oppenheimer reiterated a hold rating on shares of Teva Pharmaceutical Industries in a research report on Thursday. Finally, Maxim Group reiterated a hold rating on shares of Teva Pharmaceutical Industries in a research report on Thursday. Ten equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $21.15.

Teva Pharmaceutical Industries (NYSE:TEVA) opened at $18.61 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries has a 12-month low of $10.85 and a 12-month high of $37.94. The company has a market capitalization of $19,300.00, a price-to-earnings ratio of -1.15, a P/E/G ratio of 1.35 and a beta of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.91 EPS for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 14.52% and a negative net margin of 72.66%. The company had revenue of $5.46 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter last year, the business earned $1.38 earnings per share. Teva Pharmaceutical Industries’s revenue was down 15.9% on a year-over-year basis. analysts expect that Teva Pharmaceutical Industries will post 2.75 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2018/02/10/teva-pharmaceutical-industries-teva-releases-fy18-earnings-guidance.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit